Abstracts Archive - Page 290 of 2425 - ACR Meeting Abstracts

Abstract Number: 1897 • ACR Convergence 2023
In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care
Aos Aboabat¹, Samar Aboulenain¹, Zareen Ahmad², Medha Soowamber³ and Sindhu Johnson⁴, ¹University of Toronto, Toronto, ON, Canada, ²Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³Toronto Scleroderma Program, Mount Sinai Hospital, Toronto Western Hospital, University of Toronto, Woodbridge, ON, Canada, ⁴Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease with significant morbidity and mortality. Quality indicators (QIs) for SSc care, previously published, are essential tools…
Abstract Number: 1876 • ACR Convergence 2023
A Deep Learning System for Automated Assessing Microcirculation Abnormalities in Nailfold Capillaroscopy Images of Systemic Sclerosis
Yue Zhuang¹, Zipeng Wang², Jing Zhu³, Yongbin Yu² and Yi Liu⁴, ¹Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China, ²School of information and software engineering, University of Electronic Science and Technology of China, Chengdu, China, ³Department of Rheumatology and Immunology, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China, ⁴Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China
Background/Purpose: Detection of specific abnormalities in capillaries, named scleroderma patterns, by nailfold capillaroscopy (NFC) is one of the most important means to diagnose systemic sclerosis…
Abstract Number: 1878 • ACR Convergence 2023
MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study
Thurkka Rajeswaran¹, Emma Harris², hannah Mathieson¹, John Biglands³, Paul Stewart¹, Ai Lyn Tan¹ and Sarah Mackie⁴, ¹University of Leeds, Leeds, United Kingdom, ²The Open University, Milton Keynes, United Kingdom, ³NIHR Leeds Biomedical Research Centre and Medical Physics and Engineering , Leeds Teaching Hospitals NHS Trust Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Oral glucocorticoid therapy has many adverse effects including insulin resistance and myopathy. Long-term glucocorticoid therapy causes a "sarcopenic obesity" phenotype of adiposity with muscle…
Abstract Number: 1740 • ACR Convergence 2023
Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers
Arkaitz Mucientes¹, Martín-Núñez Gracia María², José Lisbona-Montañez³, Patricia Ruiz-Limon⁴, Rocío Redondo-Rodríguez⁵, SARA MANRIQUE⁶, Inmaculada Ureña⁵, Laura Cano-García⁵, Isabel Moreno-Indias¹, Natalia Mena Vazquez⁷ and Antonio Fernandez-Nebro⁸, ¹IBIMA Plataforma BIONAND, Málaga, Spain, ²Universidad de Málaga, Departamento de Medicina y Dermatología, Málaga, Spain, ³Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, ⁴IBIMA Plataforma BIONAND, Cordoba, Spain, ⁵Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷IBIMA, Málaga, Spain, ⁸Hospital Regional Universitario de Málaga, Malaga, Spain
Background/Purpose: The etiology of rheumatoid arthritis (RA) is not fully understood. It is accepted that RA results from the interplay of genetic and environmental factors.…
Abstract Number: 1065 • ACR Convergence 2023
Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Ogheneyoma Akpoviroro¹, Nathan Sausers², Oghenetejiro Akpoviroro³, Queeneth Uwandu¹, Myriam Castagne⁴, Elga Rodrigues⁴, Lefulesele Khoalone¹, sara Humayun¹ and Jameson Woodard¹, ¹Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, ²Pennsylvania State University, State College, PA, ³Mater Dei Hospital, Msida, Malta, ⁴Boston University, Boston, MA
Background/Purpose: Describe patients(pts) hospitalized with COVID-19C(C19) who were on disease modifying antirheumatic drugs (DMARDs) before admission(BA); assess if clinical outcomes differed from pts without BA…
Abstract Number: 1484 • ACR Convergence 2023
Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature
Katarzyna Karpinska-Leydier¹, Arseni Khorochkov², Ambar Morales-Rodriguez¹, Nur Barlas¹, Sait Barlas¹, Abraham Bell¹, Magdy El-Din³ and Shristi Basnyat⁴, ¹Florida State University - Cape Coral Hospital, Cape Coral, FL, ²Poznan University of Medical Sciences, Poznań, Poland, ³Florida State University/Lee physicians group, Cape Coral, FL, ⁴Florida State University/Lee physicians group, Fort Myers, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE). Current investigations implicate microbiome changes in disease pathogenesis, particularly pathobiont expansions of…
Abstract Number: 1084 • ACR Convergence 2023
Identifying and Addressing Disparities in Health Literacy in Patients with Rheumatic Diseases Through Point of Care Distribution of Patient Education Materials
Kelly Corbitt¹, Abhimanyu Amarnani², Jammie Law³, Cristina Sorrento³, Nicole Leung⁴, Catherine Howe³, Tasneem Ahmed³, Meghan Anderson³ and Sara Stream³, ¹New York University, El Portal, FL, ²NYU Langone Medical Center, New York, NY, ³New York University, New York, NY, ⁴New York University Langone Hospital, New York, NY
Background/Purpose: Improving health literacy in patients with rheumatic diseases is important as many have chronic, complex diagnoses treated with high-risk medications. Poor health literacy may…
Abstract Number: 1871 • ACR Convergence 2023
Utility of Infrared Thermography in Patients with Digital Gangrene
Nidhish Chandra M, Puneet Kumar, Urmila Dhakad, Shweta Bhardwaj, Sanjay Pruthviraj Buddha, Parag Vijayvergia and Lily Singh, King George Medical University, Lucknow, India
Background/Purpose: Digital gangrene has been described as a complication of several Autoimmune Inflammatory Rheumatic Diseases(AIIRD). Due to multiple underlying mechanisms causing digital gangrene in AIIRD…
Abstract Number: 1751 • ACR Convergence 2023
Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls
Namit Kumar¹, Xueer Chen², Mary Ann Aure³, Andy Ishii⁴, Laura Martinez-Prat⁵, chelsea Bentow⁴, Jasmine Saini², Michael Mahler⁴ and Laurence Menard², ¹Bristol Myers Squibb, San Diego, CA, ²Bristol Myers Squibb, Princeton, NJ, ³Werfen, Chula Vista, CA, ⁴Werfen, San Diego, CA, ⁵Werfen Autoimmunity, Sant Cugat del Vallès, Spain
Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
Abstract Number: 1070 • ACR Convergence 2023
Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon
Julien Seiller¹, Emmanuel Massy², Julien Peron³ and Cyrille Confavreux², ¹Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, Lyon, France, ²Centre Expert des Métastases Osseuses (CEMOS) - Service de Rhumatologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Université de Lyon, INSERM UMR 1033-LYOS, Lyon, France, ³Service d’oncologie médicale. Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Université de Lyon, INSERM U1290, Lyon, France
Background/Purpose: Since Immune Checkpoint Inhibitors (ICI) revolution, oncologists face immune-related adverse events (irAEs) including rheumatologic irAEs with inflammatory arthritis. Treatment of rheumatologic irAE can be…
Abstract Number: 1087 • ACR Convergence 2023
Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…
Abstract Number: 1493 • ACR Convergence 2023
Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission
Yong Yuan¹, Shanzhi He¹, Wenli Zhang², Hongyu Zhang², Vincent DeStefano³, Masayuki Wada³, Kevin Pinz³, Greg Deener³, Yu Ma⁴, Min Wang¹, Fugui Li¹, Ming Hong¹, Chanjuan Zou¹, Mingxia Wang¹, Ling Ding¹, Yingwen Liang¹, Yupo Ma³ and Weijia Wang¹, ¹Zhongshan People’s Hospital, Zhongshan, China, ²Peking University Shenzhen Hospital, Shenzhen, China, ³iCell Gene Therapeutics Inc., Stony Brook, NY, ⁴iCAR Bio Therapeutics Ltd, Zhongshan, China
Background/Purpose: Evaluate cCAR safety in SLE, LN and autoimmune conditions. Determine whether a single dose eliminates autoantibodies with well tolerated long-term, medication-free remission in open…
Abstract Number: 1868 • ACR Convergence 2023
Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial
Signe Møller-Bisgaard¹, Kim Hørslev-Petersen², Lykke Ørnbjerg¹, Bo Ejbjerg³, Merete L Hetland¹, Jakob Moeller⁴, Robin Christensen⁵, Sabrina Mai Nielsen⁶, Daniel Glinatsi⁷, Mikael Boesen⁸, Kristian Stengaard-Pedersen⁹, Ole Rintek Madsen¹⁰, Bente Jensen¹¹, Jan Alexander Villadsen², Ellen-Margrethe Hauge⁹, Oliver Hendricks², Hanne Merete Lindegaard¹², Niels Steen Krogh¹³, Anne Grethe Jurik⁹, Henrik Thomsen⁴ and Mikkel Østergaard¹⁴, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ³Slagelse Hospital, Slagelse, Denmark, ⁴Herlev-Gentofte Hospital, Herlev, Denmark, ⁵Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ⁸Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, ⁹Aarhus University Hospital, Aarhus, Denmark, ¹⁰Herlev-Gentofte Hospital, Gentofte, Denmark, ¹¹Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, ¹²Odense Hospital, Odense, Denmark, ¹³ZiteLab ApS, Frederiksberg, Denmark, ¹⁴Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Radiographic joint damage progresses in 20-30% of rheumatoid arthritis (RA) patients despite fulfilling clinical remission criteria (1). Osteitis assessed on MRI is a well…
Abstract Number: 1877 • ACR Convergence 2023
Diagnostic Yield of 18F-FDG PET-CT for Large Vessel Involvement in Patients with Suspected Giant Cell Arteritis and Negative Temporal Artery Biopsy
Javier Narvaez¹, Paula V. Estrada-Alarcón², Paola Vidal-Montal³, Iván Sánchez-Rodriguez⁴, Aida Sabate-Llobera⁴, Montserrat Cortes-Romera⁴ and Joan Miquel Nolla⁵, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Department of Nuclear Medicine – PET IDI. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Every effort should be made to confirm a suspected diagnosis of giant cell arteritis (GCA). According to the 2018 update of the EULAR recommendations…
Abstract Number: 1753 • ACR Convergence 2023
Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint
Georgios Vasileiadis¹, Anna-Karin Hultgård Ekwall², Reshmi Sureshkumar¹, Monica Guma³, Anna Rudin⁴, Yuan Zhang¹ and Cristina Maglio¹, ¹Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ³San Diego VA Healthcare Service, La Jolla, CA, ⁴Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Several metabolic pathways have been implicated in rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) aggressive phenotype1,2. Here, we aimed to analyse the full spectrum of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].